文献速递妇科

L1CAM表达与子宫内膜样卵巢癌不良结局相关,但与透明细胞卵巢癌无关

L1CAM expression associates with poor outcome in endometrioid, but not in clear cell ovarian carcinoma.
PubMed 文献 · Gynecol Oncol · 2017-06-16

研究对249例子宫内膜样和140例透明细胞卵巢癌进行L1CAM免疫组化分析,发现L1CAM在子宫内膜样癌中表达率为15%、透明细胞癌为23%。L1CAM表达与子宫内膜样癌的不良疾病特异性总生存和无病生存强相关(p<0.0001,p=0.0005),但在透明细胞癌中无此关联。L1CAM表达并非独立预后因素。

要点

  • L1CAM在子宫内膜样卵巢癌中表达率15%,在透明细胞卵巢癌中为23%。
  • L1CAM表达与子宫内膜样卵巢癌的不良总生存和无病生存强相关,但与透明细胞癌无关。
  • L1CAM表达与子宫内膜样卵巢癌的更高分级、更高分期和原发治疗反应不完全相关,但非独立预后因素。

核心结论

  • L1CAM表达可作为预测子宫内膜样卵巢癌患者临床结局和治疗反应的生物标志物,但不适用于透明细胞癌。
  • L1CAM阳性也预测同时性子宫内膜样卵巢癌和子宫内膜癌患者的不良结局。

研究设计与样本

  • 基于组织芯片的免疫组化分析,纳入249例子宫内膜样卵巢癌和140例透明细胞卵巢癌,其中57例患者同时存在子宫内膜癌。

主要发现

  • L1CAM在15%的子宫内膜样卵巢癌和23%的透明细胞卵巢癌中表达。
  • L1CAM表达与子宫内膜样卵巢癌的不良疾病特异性总生存(p<0.0001)和无病生存(p=0.0005)强相关,但在透明细胞卵巢癌中无此关联。
  • 在1-2级癌中观察到L1CAM表达与不良总生存显著相关(p<0.0001),但在3级肿瘤中无此关联。
  • 在子宫内膜样卵巢癌中,L1CAM表达与侵袭性肿瘤特征相关,如更高分级和分期、原发治疗反应不完全。
  • L1CAM表达不是总生存或无病生存的独立预后因素;57例同时性子宫内膜癌患者中,L1CAM阳性在卵巢和子宫内膜肿瘤中均阳性4例,仅在子宫内膜肿瘤中阳性3例,这7例L1CAM阳性肿瘤患者均结局不良。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Our aim was to study the expression of L1CAM in endometrioid and clear cell ovarian carcinomas and to evaluate its correlation with clinical parameters and patient prognosis. METHODS: Tissue microarray -based immunohistochemical analysis of L1CAM expression was performed in 249 endometrioid and 140 clear cell ovarian carcinomas. Concurrent endometrial carcinoma was found in 57 of these patients. RESULTS: L1CAM expression was found in 15% of endometrioid and 23% of clear cell ovarian carcinomas. L1CAM expression was strongly associated with poor disease-specific overall survival and poor disease-free survival in endometrioid (p<0.0001, p=0.0005), but not in clear cell ovarian carcinomas. Significant association of L1CAM expression with poor overall survival was observed in grade 1-2 carcinomas (p<0.0001), but not in grade 3 tumors. In endometrioid ovarian carcinomas, L1CAM expression was associated with aggressive tumor characteristics, such as higher grade and stage, and incomplete response to primary therapy. However, L1CAM expression was not an independent prognostic factor for overall or disease-free survival. Of the 57 patients with concurrent endometrial carcinoma L1CAM positivity was found in 4 cases both in the ovarian and endometrial tumors, and in 3 cases only in the endometrial tumor. All these seven patients with L1CAM positive tumors had poor outcome. CONCLUSIONS: L1CAM expression could serve as a biomarker for predicting clinical outcome and response to therapy in patients with endometrioid ovarian carcinoma, but not in clear cell carcinomas. L1CAM positivity also predicts poor outcome in patients with concurrent endometrioid ovarian and endometrial carcinomas.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Soovares P, Pasanen A, Bützow R, et al. L1CAM expression associates with poor outcome in endometrioid, but not in clear cell ovarian carcinoma. Gynecol Oncol. 2017. PMID: 28625395. doi:10.1016/j.ygyno.2017.06.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。